GSK alli agreement
This article was originally published in The Tan Sheet
GlaxoSmithKline announces Feb. 20 it has acquired from Roche exclusive rights to weight-loss drug orlistat (alli) for OTC use in markets outside the U.S. excluding Japan. Roche retains marketing rights for the orlistat product Xenical for Rx use. GSK says in a release it anticipates filing orlistat for OTC approval in Europe and other key international markets by the end of 2007. FDA approved alli for OTC use Feb. 7 and GSK plans to launch alli by this summer (1"The Tan Sheet," Feb. 12, 2007, p. 8)...
You may also be interested in...
FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy.